CRNX

Crinetics Pharmaceuticals, Inc.

45.62 USD
+0.04 (+0.09%)
Last updated
This page is just a preview of the data found in TrendSpider’s full version

Crinetics Pharmaceuticals, Inc. stock is down -6.19% since 30 days ago. The next earnings date is Aug 6, 2024. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 66.67% of the previous 5 June’s closed higher than May. In the last 10 Unusual Options Trades, there were 10 CALLs. 100% of analysts rate it a buy.

Options Flow Last 10
Date & Time Expiration Date Strike Price Trade Type Size Open Interest
13 May 18:08 21 Jun, 2024 50.00 CALL 142 3188
13 May 18:08 21 Jun, 2024 50.00 CALL 150 3188
13 May 18:08 21 Jun, 2024 50.00 CALL 132 3188
13 May 18:11 21 Jun, 2024 50.00 CALL 14581 3188
13 May 18:12 21 Jun, 2024 50.00 CALL 281 3188
15 May 14:01 21 Jun, 2024 55.00 CALL 110 3340
15 May 16:49 21 Jun, 2024 55.00 CALL 229 3340
23 May 17:20 21 Jun, 2024 50.00 CALL 500 18411
24 May 19:00 21 Jun, 2024 50.00 CALL 161 18863
07 Jun 19:08 20 Sep, 2024 60.00 CALL 200 1225

About Crinetics Pharmaceuticals, Inc.

Crinetics Pharmaceuticals, Inc. focuses on the discovery, development, and commercialization of therapeutics for rare endocrine diseases and endocrine-related tumors. The company is also developing CRN04777, an oral selective nonpeptide somatostatin type 5 receptor agonist, which is in phase I clinical trial for the treatment of congenital hyperinsulinism.

  • JP Morgan
    Tue Jun 4, 08:17
    buy
    confirm
  • Oppenheimer
    Tue Jun 4, 08:07
    buy
    confirm
  • HC Wainwright & Co.
    Tue Jun 4, 07:25
    buy
    confirm
  • Baird
    Thu May 23, 12:36
    buy
    confirm
  • Morgan Stanley
    Thu May 23, 11:22
    buy
    confirm
  • HC Wainwright & Co.
    Thu May 23, 07:13
    buy
    confirm